Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kyle Bass’ War Against Pharmaceutical Companies Goes On While The Masses Overlook China’s Real Problem

Page 1 of 2

Those who seek to profit from shorting strategies should keep a close eye on Kyle Bass’ war against the pharmaceutical industry. The founder of Hayman Capital Management has been filing inter-partes-reviews (IPRs) challenging the patents of numerous drugmakers that “allege innovation”. Bass told CNBC’s “Squawk on the Street” that he is targeting “things that are silly that shouldn’t be backed by the U.S. Patent Office”. He also mentioned his plans to file IPRs on less than 1% of the drugs on the market, claiming that “the ones that we are going after are the kind of egregious examples of evergreening, which end up costing the public at large tens of billions of dollars a year in prescription drug prices”.

Kyle Bass

But let’s first get you acknowledged with Insider Monkey’s sphere of activity. Besides providing high quality evidence-based articles, we also pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 118% since then and outperformed the S&P 500 Index by around 60 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

Kyle Bass
Kyle Bass
Hayman Advisors

Getting back to our story, Kyle Bass’ activist short strategy has not turned out successful thus far, but he is not going to give up anytime soon. Earlier this month, the Patent Trial and Appeal Board rejected the hedge fund manager’s petitions to review a patent for Biogen Inc. (NASDAQ:BIIB)’s Tecfidera. Acorda Therapeutics Inc. (NASDAQ:ACOR) represents another target of the Coalition for Affordable Drugs, formed by Bass. The Patent Trial and Appeal Board also declined to review two cases on Acorda, saying that the information provided by Bass was not publicly available. However, he has already refiled the IPRs on Acorda, which clearly indicates that he will keep up the fight.

Despite fighting the pharmaceutical industry, Bass’ Hayman Capital Management initiated a number of long positions within the industry during the second quarter. Specifically, the investment firm acquired an 836,593 share-stake in Perrigo Company Public Limited Company (NYSE:PRGO), a new stake in Mylan N.V. (NASDAQ:MYL) that consists of 780,251 shares, and a 63,675 share-position in Pfizer Inc. (NYSE:PFE), to name just a few. Therefore, the aforementioned companies will surely not serve as potential targets of Bass’ campaign.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!